According to the latest data from Truveta Research, “As of December 2025, GLP-1 RA prescriptions account for more than 7% of all prescriptions”; tirzepatide leads the pack. Side note: While overall GLP-1 prescription rates rose slightly from September through December 2025, new prescriptions declined a bit, possibly because of the holidays.